ERBA Diagnostics Enters Brazilian Sector with Leading-Edge Clinical Testing Portfolio
|
By LabMedica International staff writers Posted on 02 Nov 2014 |
|
ERBA Diagnostics, Inc. (Miami Lakes, FL, USA) has announced that an integrated portfolio of its latest in vitro diagnostics platforms and reagents are now being made available to hospitals, references labs, and physician clinics in Brazil. The product line includes a comprehensive suite of instruments, reagents, and kits for immunology, clinical chemistry, hematology, diabetes, and infectious disease testing, with an emphasis on hematology and clinical chemistry. ERBA Diagnostics intends to introduce this suite of products as the product registrations in Brazil are completed.
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Latest Industry News
- Hospital Partnership Advances Clinical Validation of Portable Diagnostic Technology
- Diazyme Expands Chemistry Testing Portfolio With Alfa Wassermann Acquisition
- Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
- Agilent Acquisition of Proscia to Advance AI-Enabled Digital Pathology Workflows
- Digital Pathology Collaboration Expands Laboratory Access to AI-Driven Diagnostics
- Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation
- European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing
- Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
- Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
- Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
- Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval
- Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
- Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
- New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing
- Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
- Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
Channels
Clinical Chemistry
view channel
Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
Cancer cachexia is a severe wasting syndrome that affects roughly half of patients with cancer and cannot be reversed simply by increasing food intake. It can reduce treatment tolerance, impair quality... Read more
Study Evaluates Alzheimer’s Blood Biomarker Across Racial and Ethnic Groups
Alzheimer’s disease trials increasingly depend on identifying cognitively unimpaired people who already have elevated brain amyloid. Blood biomarkers may help reduce reliance on positron emission tomography... Read more
Molecular Diagnostics
view channel
RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more
Blood-Based Test Improves Screening Adherence and May Reduce Colorectal Cancer Deaths
Colorectal cancer (CRC) screening depends on patient participation and completion of follow-up colonoscopy after an abnormal noninvasive result. Access barriers can make both steps difficult, particularly... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
Longitudinal Blood Analysis Tracks Changes in Childhood Allergen Sensitization
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read more
FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
Human Parvovirus B19 is a highly contagious erythrovirus transmitted mainly through respiratory droplets and close contact. Diagnosis relies on IgM antibodies to detect active infection and IgG antibodies... Read more
Microbiology
view channel
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read more
Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
Long Covid can involve persistent respiratory, cognitive, and gastrointestinal symptoms after acute infection, creating a difficult diagnostic and management challenge. Because COVID-19 initially affects... Read more
Pathology
view channel
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
Digital pathology is reshaping how laboratories manage case review, image analysis, and collaboration. As diagnostic workflows become more complex, pathology teams need platforms that can support digital... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
